Clinical Trial Update: A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating RC48-ADC in combination with Cadonilimab (AK104) for HER2-expressing locally advanced or metastatic urothelial carcinoma is underway,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Cadonilimab
• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: Shanxi Province Cancer Hospital | Conditions: Urothelial Carcinoma | Phase 2 | Status: UNKNOWN